A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
Lauren C. Harshman(Dana-Farber Cancer Institute), Anil Kapoor(People’s University), Michael A.S. Jewett(Princess Margaret Cancer Centre), Daniel J. George(Duke University), Brian Shuch(University of California, Los Angeles), Mohamad E. Allaf(Johns Hopkins University), Rupal S. Bhatt(Dana-Farber Cancer Institute), M. Dror Michaelson(Harvard University), Charles G. Drake(Columbia University Irving Medical Center), Eliezer M. Van Allen(Dana-Farber Cancer Institute), David Cella(Northwestern University), Naomi B. Haas(University of Pennsylvania), Sabina Signoretti(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Mäneka Puligandla(Dana-Farber Cancer Institute), Primo N. Lara(UC Davis Comprehensive Cancer Center), Rajan T. Gupta(Duke University), David F. McDermott(Beth Israel Deaconess Medical Center), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Daniel Yick Chin Heng(University of Calgary)
Cited by 12
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
|Journal of Clinical Epidemiology|2010|5.1k